These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28461099)

  • 121. The Potential of Optimized Liposomes in Enhancement of Cytotoxicity and Apoptosis of Encapsulated Egyptian Propolis on Hep-2 Cell Line.
    El-Aziz EAEA; Elgayar SF; Mady FM; Abourehab MAS; Hasan OA; Reda LM; Alaaeldin E
    Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959465
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Cytotoxic Potential, Metabolic Profiling, and Liposomes of
    Musa A; Elmaidomy AH; Sayed AM; Alzarea SI; Al-Sanea MM; Mostafa EM; Hendawy OM; Abdelgawad MA; Youssif KA; Refaat H; Alaaeldin E; Abdelmohsen UR
    Int J Nanomedicine; 2021; 16():3861-3874. PubMed ID: 34113103
    [TBL] [Abstract][Full Text] [Related]  

  • 123. The co-delivery of oxaliplatin abrogates the immunogenic response to PEGylated siRNA-lipoplex.
    Alaaeldin E; Abu Lila AS; Moriyoshi N; Sarhan HA; Ishida T; Khaled KA; Kiwada H
    Pharm Res; 2013 Sep; 30(9):2344-54. PubMed ID: 23673556
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
    Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
    Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Systemically Administered RNAi Molecule Sensitizes Malignant Pleural Mesotheliomal Cells to Pemetrexed Therapy.
    Abu Lila AS; Fukushima M; Huang CL; Wada H; Ishida T
    Mol Pharm; 2016 Nov; 13(11):3955-3963. PubMed ID: 27740765
    [TBL] [Abstract][Full Text] [Related]  

  • 126. A simplified method for manufacturing RNAi therapeutics for local administration.
    Ando H; Abu Lila AS; Fukushima M; Matsuoka R; Shimizu T; Okuhira K; Ishima Y; Huang CL; Wada H; Ishida T
    Int J Pharm; 2019 Jun; 564():256-262. PubMed ID: 31015002
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
    Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Co-administration of liposomal l-OHP and PEGylated TS shRNA-lipoplex: A novel approach to enhance anti-tumor efficacy and reduce the immunogenic response to RNAi molecules.
    Alaaeldin E; Abu Lila AS; Ando H; Fukushima M; Huang CL; Wada H; Sarhan HA; Khaled KA; Ishida T
    J Control Release; 2017 Jun; 255():210-217. PubMed ID: 28461099
    [TBL] [Abstract][Full Text] [Related]  

  • 129. The Challenge to Deliver Oxaliplatin (l-OHP) to Solid Tumors: Development of Liposomal l-OHP Formulations.
    Matsuo NCA; Ando H; Doi Y; Shimizu T; Ishima Y; Ishida T
    Chem Pharm Bull (Tokyo); 2022; 70(5):351-358. PubMed ID: 35491191
    [TBL] [Abstract][Full Text] [Related]  

  • 130. [Elucidation for Intratumor Localization of a DDS-based Anticancer Drug and Enhancement of Its Therapeutic Effects via Improvement of the Tumor Microenvironment].
    Ando H
    Yakugaku Zasshi; 2021; 141(11):1241-1245. PubMed ID: 34719544
    [TBL] [Abstract][Full Text] [Related]  

  • 131. An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers.
    Ando H; Ishida T
    Adv Drug Deliv Rev; 2020; 154-155():27-36. PubMed ID: 32781056
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin.
    Lila AS; Kiwada H; Ishida T
    Biol Pharm Bull; 2014; 37(2):206-11. PubMed ID: 24492717
    [TBL] [Abstract][Full Text] [Related]  

  • 133. [Development of siRNA delivery strategy by active control of tumor microenvironment].
    Ishida T; Kiwada H
    Yakugaku Zasshi; 2013; 133(3):379-86. PubMed ID: 23449418
    [TBL] [Abstract][Full Text] [Related]  

  • 134.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 135.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 136.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 137.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 138.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 139.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 140.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.